Darbepoietin Alfa

Phase 2Small molecule

RRegion Stockholm

Darbepoietin Alfa is one of 36 small molecule programs targeting Nephropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NephropathyActive, not recruiting

NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

131 competitors in Nephropathy

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

7 2

Zemplar

AbbVie

Phase 3

1 3

Simulect

Novartis

Phase 3

1 4

Ultomiris

AstraZeneca

Phase 3

—5

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 3

3 6

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

1 7

Aurlumyn

BBTG International Inc.

Phase 3

1 8

Campath

GGenzyme, a Sanofi Company

Phase 3

1 9

Epoetin Beta

Roche

Phase 3

1 10

Povetacicept

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Nephropathy

NCT05810311

Clinical

Trials by Indication[1]

Nephropathy1 trial

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

Not yet recruiting·RRegion Stockholm·Phase 2·NCT05810311·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Darbepoietin Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Darbepoietin Alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Darbepoietin Alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Stockholm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRegion Stockholm

Darbepoietin Alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Nephropathy1 trial

References

Drug Info

Quick Facts

Related News